UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.478

Sortiert nach

Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS

International psychogeriatrics, 2020-02, Vol.32 (2), p.267-277

2020

Volltextzugriff (PDF)

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

Alzheimer's & dementia : translational research & clinical interventions, 2019, Vol.5 (1), p.354-363

2019

Volltextzugriff (PDF)

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Journal of headache and pain, 2020-10, Vol.21 (1), p.123-123, Article 123

2020

Volltextzugriff (PDF)

Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: A matched, retrospective study of US Medicare beneficiaries

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2019-12, Vol.11 (1), p.125-135

2019

Volltextzugriff (PDF)

Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease

Journal of Alzheimer's disease, 2018-01, Vol.61 (1), p.295

2018

Volltextzugriff (PDF)

Response to van Dyck, O'Dell, & Mecca letter to the editor regarding Andrews et al. (2019)

Alzheimer's & dementia : translational research & clinical interventions, 2023-04, Vol.9 (2), p.e12387-n/a

2023

Volltextzugriff (PDF)

Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure

Cephalalgia reports, 2021, Vol.4, p.251581632110156

2021

Volltextzugriff (PDF)

The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective

Value in health, 2013-03, Vol.16 (2), p.334-344

2013

Volltextzugriff (PDF)

Disease severity at the time of initial cognitive assessment is related to prior health‐care resource use burden

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2020, Vol.12 (1), p.e12093-n/a

2020

Volltextzugriff (PDF)

A systematic literature review on the global epidemiology of Dravet syndrome and Lennox–Gastaut syndrome: Prevalence, incidence, diagnosis, and mortality

Epilepsia (Copenhagen), 2024-05, Vol.65 (5), p.1240-1263

2024

Volltextzugriff (PDF)

A comprehensive systematic literature review of the burden of illness of Lennox–Gastaut syndrome on patients, caregivers, and society

Epilepsia (Copenhagen), 2024-05, Vol.65 (5), p.1224-1239

2024

Volltextzugriff (PDF)

The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective—Author Response to Letter to the Editor

Value in health, 2013-12, Vol.16 (8), p.1173-1174

2013

Volltextzugriff (PDF)

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache

Headache, 2020-11, Vol.60 (10), p.2254-2264

2020

Volltextzugriff (PDF)

Revised criteria for the diagnosis and staging of Alzheimer’s disease

Nature medicine, 2024-06

2024

Volltextzugriff (PDF)

One‐Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study

Journal of the American Geriatrics Society (JAGS), 2018-05, Vol.66 (5), p.969-975

2018

Volltextzugriff (PDF)

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Alzheimer's & dementia, 2024-06

2024

Volltextzugriff (PDF)

The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making

The patient : patient-centered outcomes research, 2022-09, Vol.15 (5), p.551-564

2022

Volltextzugriff (PDF)

Assessing the economic burden of Alzheimer's disease patients first diagnosed by specialists

BMC geriatrics, 2016-07, Vol.16 (1), p.138-138, Article 138

2016

Volltextzugriff (PDF)

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

Journal of pain research, 2021-01, Vol.14, p.2059-2070

2021

Volltextzugriff (PDF)

Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2017, Vol.6 (1), p.65-74

2017

Volltextzugriff (PDF)

Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective

Applied health economics and health policy, 2013-06, Vol.11 (3), p.219-236

2013

Volltextzugriff (PDF)

AAV serotype 2 1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice

Gene therapy, 2012-07, Vol.19 (7), p.724-733

2012

Volltextzugriff (PDF)

Comment on: "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective"/Authors' Reply to Liedgens and Henske: "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective"

Applied health economics and health policy, 2013-10, Vol.11 (5), p.553

2013

Volltextzugriff (PDF)

From Rational to Relevant: What Counts as “Public” Knowledge?

Global Academe, p.39-50

Volltextzugriff (PDF)

Hypothermia for Intracranial Hypertension after Traumatic Brain Injury

The New England journal of medicine, 2015-12, Vol.373 (25), p.2403-2412

2015

Volltextzugriff (PDF)

1 – 25 von 1.478

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.353)
Mit Volltextzugriff
(1.239)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: A matched, retrospective study of US Medicare beneficiaries

Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease

Response to van Dyck, O'Dell, & Mecca letter to the editor regarding Andrews et al. (2019)

Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure

The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective

Disease severity at the time of initial cognitive assessment is related to prior health‐care resource use burden

A systematic literature review on the global epidemiology of Dravet syndrome and Lennox–Gastaut syndrome: Prevalence, incidence, diagnosis, and mortality

A comprehensive systematic literature review of the burden of illness of Lennox–Gastaut syndrome on patients, caregivers, and society

The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective—Author Response to Letter to the Editor

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache

Revised criteria for the diagnosis and staging of Alzheimer’s disease

One‐Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making

Assessing the economic burden of Alzheimer's disease patients first diagnosed by specialists

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey

Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective

AAV serotype 2 1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice

Comment on: "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective"/Authors' Reply to Liedgens and Henske: "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective"

From Rational to Relevant: What Counts as “Public” Knowledge?

Hypothermia for Intracranial Hypertension after Traumatic Brain Injury

Suchergebnisse filtern